Business Tax Working Group discusses cuts to R&D Tax Incentive
23 August, 2012 by AusBiotechAusBiotech invites members’ comments on the recently released Business Tax Working Group (BTWG) discussion paper, which includes amongst its issues for discussion four options that seek to limit the R&D Tax Incentive to companies with turnover over $20 million.
GI Dynamics gets FDA provisional nod for pivotal EndoBarrier trial
23 August, 2012 by Dylan Bushell-EmblingThe US FDA has provisionally cleared GI Dynamics (ASX:GID) to jump straight to a full clinical trial of EndoBarrier to treat Type 2 diabetes patients who are obese.
Mesoblast stem cell R&D spend triples
22 August, 2012 by Tim DeanMesoblast (ASX:MSB) has reinvested a sizeable chunk of the revenues from its licensing deal with Cephalon into boosting research and development efforts for its adult stem cell technology, bumping up total expenses by more than $58 million in FY12.
Oncology start-up Senz gets seed funding for chemo agent
22 August, 2012 by Dylan Bushell-EmblingStart-up Senz Oncology has secured seed funding to support the development of a chemotherapeutic agent as a potential treatment for acute leukaemias.
CSL lifts FY12 profit to US$1 billion
22 August, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) grew its FY12 net profit 4.5% to $983 million, despite taking a significant hit on exchange rates.
BioDiem viral vector research clears first hurdle
21 August, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and French partner VIVALIS have reached two significant milestones in their work towards the development of a new viral vector.
PM’s Manufacturing Taskforce reports
21 August, 2012 by AusBiotechNon-government members of the Prime Minister's Manufacturing Taskforce, representing business, unions and the research sector, have released their report Smarter Manufacturing for a Smarter Australia, after the group was established in late 2011.
Bioniche launching more animal health products
21 August, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) has launched an equine inflammation treatment in the US, and scored Canadian distribution rights for six more products.
QRxPharma meets with FDA about MoxDuo IR knockback
20 August, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) executives left a pivotal meeting with the US FDA hopeful of being able to avoid prolonging the MoxDuo IR approvals process with another clinical trial.
Manufacturing Taskforce largely overlooks biotechnology
17 August, 2012 by Tim DeanThe Prime Minister’s Manufacturing Taskforce report from non-government members, released yesterday, has focused largely on traditional manufacturing with little attention given to the biotechnology, pharmaceutical and medical device manufacturing sectors.
AusBiotech national office on the move…
16 August, 2012 by AusBiotechThe national office of AusBiotech will move this weekend from its current location in Malvern to Level 4, 627 Chapel Street, South Yarra Victoria.
Opinion: Scrapping the R&D tax incentive is hardly a smart idea for economic policy
16 August, 2012 by Staff WritersThe Business Tax Working Group discussion paper’s suggestion to reduce the R&D tax incentive reveals a clear-cut attitude to policy aimed at Australia’s economic development: “It’s all about the tax take.”
Government quells concerns about R&D Tax Incentive
16 August, 2012 by Tim DeanIndustry Minister Greg Combet has moved to quell concerns that the fledgling R&D Tax Incentive could be trimmed in order to help fund a cut to the corporate tax rate, as raised by the government’s Business Tax Working Group discussion paper.
Cancer Therapeutics licences breast cancer programs
16 August, 2012 by Dylan Bushell-EmblingTwo FAK inhibitors developed by Australia's Cancer Therapeutics CRC – which are showing promise in treating triple-negative breast cancers and other solid tumours – are on their way to commercialisation.
Immuron testing anti-influenza drug against swine flu
15 August, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has started a new round of animal studies for its IMM-255 OTC influenza treatment candidate, this time in the swine flu strain.
